Pharmaceutical

Nouscom extends Series C round to $82m for cancer vaccine trials

Nouscom is part of a cancer vaccine landscape that has recently jump-started following years of dormancy.

Mar 22, 2024 - 00:00
Nouscom extends Series C round to $82m for cancer vaccine trials
Nouscom is part of a cancer vaccine landscape that has recently jump-started following years of dormancy.
Read the original article

Tags:

Previous Article

Early AMR pipeline looks beyond traditional antibiotics

Next Article

Keytruda combination treatment for NSCLC falls short in Phase III

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Leading innovators in zinc-based medicinal compositions for the pharmaceutical industry

Leading innovators in zinc-based medicinal compositions...

May 8, 2023

Emergent joins mpox fight with 50,000 vaccine dose donation to Africa

Emergent joins mpox fight with 50,000 vaccine dose dona...

Aug 21, 2024

FDA grants fast track status to FELIQS’s FLQ-101 to prevent ROP

FDA grants fast track status to FELIQS’s FLQ-101 to pre...

Nov 5, 2024